Literature DB >> 24898973

Effects of impaired renal function on levels and performance of D-dimer in patients with suspected pulmonary embolism.

H Robert-Ebadi1, L Bertoletti, C Combescure, G Le Gal, H Bounameaux, M Righini.   

Abstract

Clinical probability and D-dimer measurement play an essential role in the non-invasive diagnostic strategies for pulmonary embolism (PE). PE can be ruled out without further imaging in patients with non-high clinical probability and negative D-dimer. D-dimer level is increased in patients with renal impairment. Whether its diagnostic usefulness is maintained in these patients is not well determined. We aimed to evaluate the effects of renal impairment on diagnostic performances of D-dimer in patients with suspected PE. A retrospective analysis of 1,625 patients with suspected PE included in a multicentre prospective study was performed. D-dimer levels and percentages of patients with a negative D-dimer were compared between three subgroups according to glomerular filtration rate (GFR) estimated by the MDRD formula: ≥90 ml/min (normal renal function), 60-89 ml/min (mild renal impairment), 30-59 ml/min (moderate renal impairment). D-dimer levels increased and the proportion of negative D-dimer decreased significantly according to renal status: 46% negative D-dimer in patients with normal GFR, 31% in patients with mild renal impairment, 11% in those with moderate renal impairment, corresponding to number of patients needed to test to obtain one negative test of 2.2, 3.2 and 9, respectively. In conclusion, the clinical usefulness of D-dimer decreases with renal impairment. However, PE can still be ruled out by negative D-dimer in a substantial proportion of patients with non-high clinical probability, avoiding exposure to contrast media.

Entities:  

Keywords:  Creatinine; D-dimer; glomerular filtration rate; pulmonary embolism; renal insufficiency

Mesh:

Substances:

Year:  2014        PMID: 24898973     DOI: 10.1160/TH13-12-1024

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  6 in total

1.  D-dimer as a marker of acute pyelonephritis in infants younger than 24 months with urinary tract infection.

Authors:  Jung Won Lee; Sun Mi Her; Ji Hong Kim; Keum Hwa Lee; Michael Eisenhut; Se Jin Park; Jae Il Shin
Journal:  Pediatr Nephrol       Date:  2018-01-06       Impact factor: 3.714

2.  The diagnostic performance of renal function-adjusted D-dimer testing in individuals suspected of having venous thromboembolism.

Authors:  Vincent Ten Cate; Markus Nagler; Marina Panova-Noeva; Lisa Eggebrecht; Natalie Arnold; Heidrun Lamparter; M Iris Hermanns; Hugo Ten Cate; Martin H Prins; Christine Espinola-Klein; Thomas Münzel; Karl J Lackner; Philipp S Wild; Jürgen H Prochaska
Journal:  Haematologica       Date:  2019-03-14       Impact factor: 9.941

3.  Role of D-Dimer testing in venous thromboembolism with concomitant renal insufficiency in critical care.

Authors:  Carmen A Pfortmueller; Gregor Lindner; Georg-Christian Funk; Alexander B Leichtle; Georg M Fiedler; Christoph Schwarz; Aristomenis K Exadaktylos
Journal:  Intensive Care Med       Date:  2016-12-23       Impact factor: 17.440

4.  Mechanisms and mitigating factors for venous thromboembolism in chronic kidney disease: the REGARDS study.

Authors:  K L Cheung; N A Zakai; P W Callas; G Howard; B K Mahmoodi; C A Peralta; S E Judd; M Kurella Tamura; M Cushman
Journal:  J Thromb Haemost       Date:  2018-08-09       Impact factor: 5.824

5.  Early predictors of acute kidney injury in COVID-19 patients.

Authors:  Cigdem Yildirim; Hasan Selcuk Ozger; Emre Yasar; Nazrin Tombul; Ozlem Gulbahar; Mehmet Yildiz; Gulendam Bozdayi; Ulver Derici; Murat Dizbay
Journal:  Nephrology (Carlton)       Date:  2021-02-09       Impact factor: 2.358

6.  Evaluation of the prothrombin fragment 1.2 in patients with coronavirus disease 2019 (COVID-19).

Authors:  Hanny Al-Samkari; Fei Song; Elizabeth M Van Cott; David J Kuter; Rachel Rosovsky
Journal:  Am J Hematol       Date:  2020-09-02       Impact factor: 13.265

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.